Ms Direct (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Ms Direct, is an opioid analgesic presented as an oral dosage form for oral use. It provides potent pain relief for patients experiencing severe acute pain, cancer‑related pain, or post‑operative discomfort, and is indicated for adult patients who require strong opioid therapy.

GNH USA supplies Ms Direct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Morphine Sulfate is an opioid analgesic used to manage pain conditions that involve the central nervous system.

- Severe acute pain: provides rapid, strong analgesia for intense short‑term pain episodes. - Cancer pain: helps control persistent pain associated with malignant disease. - Post‑operative pain: reduces pain after surgical procedures to facilitate recovery.

Morphine Sulfate may cause a range of adverse reactions, varying from common to serious.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dizziness - Sweating - Itching

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Adrenal insufficiency - Dependence or withdrawal syndrome - Serotonin syndrome - Anaphylaxis

When prescribing Morphine Sulfate, clinicians should observe several safety precautions to minimize risk.

- Assess pain severity and opioid tolerance: evaluate before initiating therapy. - Monitor respiratory function: watch for signs of depression, especially after dose changes. - Avoid use in patients with significant respiratory disease: contraindicated in severe COPD or sleep apnea. - Use lowest effective dose and limit duration: reduce risk of dependence. - Educate patients on constipation management: prescribe laxatives or stool softeners. - Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Morphine Sulfate can interact with other medicines, altering its effects or increasing adverse risks.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, barbiturates): may potentiate respiratory depression. - Monoamine oxidase inhibitors (MAOIs): can cause severe hypertension or serotonin syndrome. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase morphine plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect. - Diuretics and antihypertensives: may enhance hypotensive effects.